Because the existing research data cannot fully prove the advantages of single-site Da Vinci robotic surgery (RSS) compared with single-site laparoscopic surgery (LESS) in the treatment of gynecological diseases.We aimed to evaluate the effectiveness and cost of RSS and LESS in the treatment of gynecological diseases.To provide theoretical basis for whether RSS can replace LESS in the treatment of gynecological diseases.A systematic search of three electronic databases for articles published up to December 31st,2023 was performed by computer.After literature screening,data extraction and quality evaluation according to inclusion and exclusion criteria, meta-analysis was performed using RevMan 5.1 software.A total of 16 articles were included, including 14 articles on effectiveness, and 2 articles on cost.Among them,5 studies scored 9 points for quality evaluation,3 studies scored 8 points, and 8 studies scored 7 points.Compared with LESS, RSS was associated with a shorter total operative time for malignant tumor surgery[107 patients MD-24.01 min, 95% CI-32.40 to -15.62,p <0.00001],a less estimated blood loss[107 patients MD-53.60 ml, 95% CI-105.50 to -1.69,p =0.04],and there was no significant differences in postoperative hospital days and postoperative complications between the two groups. However,Subgroup analysis of TOT separately was carried out according to the time of study publication and different single point port and robotic surgical system. After 2020 and for using commercial single point ports other than the Da Vinci dedicated single point port, or using the fourth-generation Da Vinci SP surgical system, while neither total operative time was no significant difference between the two groups[1259 patients MD 16.91 min, 95% CI -9.38 to 43.19,p = 0.21][354 patients MD 34.13 min, 95% CI -16.75 to 85.01,p = 0.19 and 645 patients MD 13.79 min, 95% CI -26.85 to 54.43,p = 0.51,respectively].Therefore,the present meta-analysis supports that comparing with LESS,in gynecological malignant tumor surgery,RSS takes shorter total operation time,less estimated blood loss,and similar efficacy in postoperative hospital days and postoperative complications. Therefore,if the cost of RSS can be reduced,RSS is a feasible surgical method for patients undergoing gynecological malignant tumor surgery.With the fourth generation Da Vinci SP surgical system,the era of single-site robotic surgery may be ushered in after 2020.